Evidence map›Paper›PMID 31571509›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2019

Conformational restriction of a type II FMS inhibitor leading to discovery of 5-methyl-

Daseul Im, Hyungwoo Moon, Jingwoong Kim, Youri Oh, Miyoung Jang, Jung-Mi Hah

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Rational design and synthesis of 2-(1Journal of enzyme inhibition and medicinal chemistry · 2022
    Article
  4. Discovery of 5-methyl-Journal of enzyme inhibition and medicinal chemistry · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daseul ImCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University , Ansan , Korea.
Hyungwoo MoonCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University , Ansan , Korea.
Jingwoong KimCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University , Ansan , Korea.
Youri OhCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University , Ansan , Korea.
Miyoung JangCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University , Ansan , Korea.
Jung-Mi HahCollege of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University , Ansan , Korea.
Hanyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of 4-arylamido 5-methylisoxazole derivatives incorporating benzimidazole was designed and synthesised by conformational restriction of an in-house type II FMS inhibitor. Kinase profiling of one compound revealed interesting features, with increased inhibitory potency towards FLT3 and concomitant loss of potency towards FMS. Several benzimidazole derivatives

Indexed as

BenzimidazolesDrug Discoveryfms-Like Tyrosine Kinase 3Hydrophobic and Hydrophilic InteractionsInhibitory Concentration 50IsoxazolesMolecular ConformationMolecular Docking SimulationProtein BindingProtein Kinase InhibitorsStructure-Activity RelationshipBenzimidazolesfms-Like Tyrosine Kinase 3IsoxazolesProtein Kinase Inhibitorsbenzimidazoleconformational restrictionFLT3FMS

Identifiers

PMID31571509
PMCPMC6781469
OpenAlexW2977510794

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.